. Author manuscript; available in PMC: 2014 Sep 5.
Published in final edited form as: Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095
Competing interests
J.P.A. is a primary inventor of intellectual property “Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling” licensed by the University of California to Bristol-Myers Squibb. Memorial Sloan-Kettering Cancer Center and Icahn School of Medicine at Mount Sinai filed a joint patent for the use of NDV for cancer immunotherapy. J.D.W. is an Advisory Board Member to Bristol-Myers Squibb and Medimmune.